Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.
Top 5 Biosimilar Articles of 2024

December 28th 2024

The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.

Paper with FDA approved on top of a magnifying glass and a keyboard | Image Credit: Pawel - stock.adobe.com
5 Key Drug Approvals and CRLs in 2024

December 27th 2024

FDA approval with stamp. | Image Credit: Surendra - stock.adobe.com
FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

December 20th 2024

AJMC
Uptake of Rituximab Biosimilars in Medicare and Medicaid in 2019-2022

December 16th 2024

Seattle Washington skyline | Image Credit: © espiegle - stock.adobe.com
From Approval to Practice: Addressing the Hurdles in Biosimilar Integration

December 12th 2024

More News

Kashyap Patel, MD
September 10th 2021

Dr Kashyap Patel Highlights How the Pandemic Influenced Utilization of Pegfilgrastim Biosimilars

Reducing the risks of secondary neutropenia, exposure to COVID-19, mortality, and financial toxicity were all major reasons the use of pegfilgrastim biosimilar gained traction during the pandemic, said Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care.
2 men shaking hands
September 10th 2021

Sandoz, Bio-Thera Solutions Enter Deal to Commercialize Avastin Biosimilar

Skylar Jeremias
Bio-Thera Solutions and Sandoz have partnered for to allow for the commercialization of BAT1706, a bevacizumab biosimilar referencing Avastin, for the treatment of several forms of cancer.
Neal Dave, PharmD
September 3rd 2021

Dr Neal Dave Expresses Excitement for the First PD-1 Inhibitor Biosimilar

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discussed physician anticipation for the first biosimilars for programmed death (PD)-1 inhibitors.
women wearing pink shirt and pink ribbons
September 2nd 2021

Saudi Researchers Call for Greater Use of Trastuzumab Biosimilars to Offset Breast Cancer Costs

Skylar Jeremias
Switching from Herceptin (reference trastuzumab) to trastuzumab biosimilars could significantly reduce direct medication costs attributed to breast cancer management in Saudi Arabia, researchers concluded.
Neal Dave, PharmD
August 27th 2021

Dr Neal Dave: Are Physicians Excited for More Biosimilars to Enter the Oncology Space?

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the anticipation for more biosimilars to enter the oncology market and the current level of interest in the pipeline.
female doctor writing on a clipboard while speaking with a male patient
August 24th 2021

Study Confirms Overall Survival in DLBCL Is Comparable Between Rituximab Biosimilars and Rituxan

Skylar Jeremias
In comparison with reference rituximab (Rituxan), the use of rituximab biosimilars in combination therapy produced similar 3-year overall survival among patients with large-B-cell lymphoma (DLBCL), investigators concluded.
Site Logo
August 23rd 2021

Site of Care Potentially Limits Cost Savings From Biosimilars

Jessica Chang, MA Pinar Karaca-Mandic, PhD Ronald S. Go, MD Stephen Schondelmeyer, PharmD, PhD Daniel Weisdorf, MD Molly Moore Jeffery, PhD, MPP
Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings.
Dr Neal Dave Explains Why Biosimilars Should Be Favored Over Reference Products
August 20th 2021

Dr Neal Dave Explains Why Biosimilars Should Be Favored Over Reference Products

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discusses the potential for biosimilar utilization to grow and the reasons why his practice favors them over reference products.
man receiving chemotherapy from a doctor
August 19th 2021

Switching to a Pegfilgrastim Biosimilar May Facilitate Access to Chemotherapy

Skylar Jeremias
Switching patients from reference pegfilgrastim to a biosimilar could lead to substantial cost savings, with potential to offset the cost of and allow for greater access to chemotherapy treatment, investigators concluded.
3 syringes front of a bright green background
August 12th 2021

2020 Spend and Trend Report Shows Biosimilar Competition Led to Decreases in Originator Prices, Claims

Skylar Jeremias
A 2020 trends report from Artemetrx showed how biosimilar competition has contributed to lower average sales prices and claim percentages for originator products, suggesting that biosimilars are making a difference despite slow uptake.
Neal Dave, PharmD
August 6th 2021

Neal Dave, PharmD, Discusses the Importance of Consistently Reevaluating the Cost-Effectiveness of Biosimilars

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the importance of conducting regular evaluations to ensure that prescribing the most cost-effective option, whether that be a biosimilar or the reference product.
needle in a vial
August 5th 2021

Real-world Evidence Shows Good Acceptance of Rituximab Biosimilar for NHL, CLL

Skylar Jeremias
In one of the first studies to examine real-world evidence on rituximab biosimilars in the United States, investigators found that many providers treating patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are regularly prescribing a biosimilar rituximab.
Gary Lyman, MD, MPH
July 31st 2021

Dr Gary Lyman: Do Financial Incentives or Policies Have a Greater Influence on Biosimilar Uptake?

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how financial incentives, concerns for patients, and interchangeability impact biosimilar prescribing patterns.
doctor speaking to woman receiving chemotherapy
July 26th 2021

Alliance for Patient Access Releases Paper on Biosimilar Best Practices in Oncology

Skylar Jeremias
Two oncologists dive into the reasons behind physician hesitancy and unwillingness to prescribe biosimilars to patients with cancer and make suggestions on how to increase confidence in these agents.
Gary Lyman, MD, MPH
July 23rd 2021

Dr Gary Lyman: Uptake of Filgrastim vs Pegfilgrastim Biosimilars

Gary Lyman, MD, MPH, an oncologist and hematologist, compares the uptake of filgrastim biosimlars with pegfilgrastim biosimilars.
woman with Neulasta Onpro injector on her arm
July 19th 2021

FDA Cautions Amgen Against Advertisements Misrepresenting Neulasta Onpro as Superior to Biosimilars

Skylar Jeremias
Amgen has received a letter from the FDA cautioning it against making misleading claims in advertising about its pegfilgrastim injector.
Gary Lyman, MD, MPH, University of Washington
July 17th 2021

Dr Gary Lyman: Do Health Care Institutions Need to Do More to Promote Biosimilar Uptake?

Gary Lyman, MD, MPH, an oncologist and hematologist, gives his thoughts on whether health care institutions need to be doing more to encourage use of biosimilars.
6 syringes lined up next to one another
July 15th 2021

Originator Drugs Experience Price Drops When Multiple Biosimilars Are Added to Reimbursement Lists

Skylar Jeremias
The price of reference products reduced each time a new biosimilar was added to a drug program’s reimbursement list, supporting the notion that reimbursing biosimilars creates more competition and lowers drug costs, according to a Polish study.
Gary Lyman, MD, MPH
July 9th 2021

Dr Gary Lyman Compares Biosimilar Uptake in Oncology vs Other Therapeutic Areas

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how biosimilars have fared in the oncology space compared to other therapeutic areas.
several syringes over a bright green background
July 7th 2021

Patient Advocacy Organizations Join Forces to Endorse BIOSIM Act

Twenty-eight patient advocacy groups wrote a letter pledging endorsement of the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, a bill aimed at increasing reimbursement and incentivizing prescriptions for biosimilars.
Ivo Abraham, PhD, RN
July 2nd 2021

Dr Ivo Abraham on the Pandemic's Effect on Biosimilar Utilization

Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice, discusses how the COVID-19 pandemic is likely to impact oncology biosimilar utilization.
Ivo Abraham, PhD, RN
June 24th 2021

Dr Ivo Abraham: Biosimilar Pegfilgrastims vs Neulasta Onpro Utilization

Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice, talks about the role that the pandemic has played in the struggle between biosimilar pegfilgrastims and the on-body injector version of the reference product.
computerized makeup of a piece of paper with a magnifying glass over it
June 23rd 2021

Xcenda Report Shows Biosimilar Competition Lowered Drug Prices of Reference Oncology Biologics

Skylar Jeremias
A report from Xcenda showed that biosimilars for 8 blockbuster reference biologics have successfully kept drug prices from increasing by an average of 56%, restoring the possibility that biosimilars could achieve significant discounts despite facing several barriers to uptake.
Macmillan
June 19th 2021

Biosimilars Drive Savings in Medicare’s Oncology Care Model

Keely Macmillan, MSPH
Ivo Abraham, PhD, RN
June 18th 2021

Dr Ivo Abraham on How Neulasta Onpro Is Impacting the Biosimilars Space

Ivo Abraham, PhD, RN, a professor in the Department of Pharmacy Practice at University of Arizona Health Sciences, talks about the results from his cost-efficiency studies and how Amgen’s Onpro pegfilgrastim device has affected cancer care and costs.
Ivo Abraham, PhD, RN
June 11th 2021

Dr Ivo Abraham Details the Current State of G-CSF Biosimilars in the US

Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice, discusses the current state of the granulocyte-colony stimulating factor (G-CSF) sector of the biosimilar market.
man holding tablet projecting graphs
June 7th 2021

Better Uptake Found for Recently Launched vs Older Biosimilars

Skylar Jeremias
A study examining how US biosimilar uptake has evolved found that biosimilars launched more recently have seen better uptake than biosimilars that have been on the market for a longer period.
person wearing rubber gloves filling a subcutaneous syringe with a teal liquid
June 2nd 2021

High-Concentration Adalimumab Biosimilar Yields Positive 1-Year Data

Skylar Jeremias
Celltrion Healthcare’s high-concentration adalimumab biosimilar demonstrated comparable safety, efficacy, and immunogenicity profiles to the reference product for up to a year, providing further evidence supporting use of the product.
Sonia T. Oskouei, PharmD, BCMAS, DPLA, Cardinal Health
June 1st 2021

Dr Sonia Oskouei Differenciates Pharmacist Concerns From Physicians' Regarding Biosimilars

Sonia T. Oskouei, PharmD, BCMAS, DPLA, from Cardinal Health, talks about the differences between provider and pharmacist concerns and whether health organizations giving more power to pharmacists causes conflict with physicians.
Sonia T. Oskouei, PharmD, BCMAS, DPLA, Cardinal Health
May 26th 2021

Dr Sonia Oskouei Discusses the Potential for the First Interchangeable Biosimilar

Sonia T. Oskouei, PharmD, BCMAS, DPLA, from Cardinal Health, explains the ramifications that interchangeability designations will have on biosimilars and when we might see the first interchangeable biosimilar in the United States.
<1
...
5678910111213
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo